OBJECTIVES: This study was conducted to evaluate mineral metabolism markers as potential risk factors for calcific aortic valve disease. BACKGROUND: Mineral metabolism disturbances are common among older people and may contribute to cardiac valvular calcification. Associations of serum mineral metabolism markers with cardiac valvular calcification have not been evaluated in a well-characterized general population of older adults. METHODS: We measured serum levels of phosphate, calcium, parathyroid hormone, and 25-hydroxyvitamin D in 1,938 Cardiovascular Health Study participants who were free of clinical cardiovascular disease and who underwent echocardiographic measurements of aortic valve sclerosis (AVS), mitral annular calcification (MAC), and aortic annular calcification (AAC). We used logistic regression models to estimate associations of mineral metabolism markers with AVS, MAC, and AAC after adjustment for relevant confounding variables, including kidney function. RESULTS: The respective prevalences of AVS, MAC, and AAC were 54%, 39%, and 44%. Each 0.5 mg/dl higher serum phosphate concentration was associated with greater adjusted odds of AVS (odds ratio [OR]: 1.17, 95% confidence interval [CI]: 1.04 to 1.31, p = 0.01), MAC (OR: 1.12, 95% CI: 1.00 to 1.26, p = 0.05), and AAC (OR: 1.12, 95% CI: 0.99 to 1.25, p = 0.05). In contrast, serum calcium, parathyroid hormone, and 25-hydroxyvitamin D concentrations were not associated with aortic or mitral calcification. CONCLUSIONS: Higher serum phosphate levels within the normal range were associated with valvular and annular calcification in a community-based cohort of older adults. Phosphate may be a novel risk factor for calcific aortic valve disease and warrants further study.
OBJECTIVES: This study was conducted to evaluate mineral metabolism markers as potential risk factors for calcific aortic valve disease. BACKGROUND:Mineral metabolism disturbances are common among older people and may contribute to cardiac valvular calcification. Associations of serum mineral metabolism markers with cardiac valvular calcification have not been evaluated in a well-characterized general population of older adults. METHODS: We measured serum levels of phosphate, calcium, parathyroid hormone, and 25-hydroxyvitamin D in 1,938 Cardiovascular Health Study participants who were free of clinical cardiovascular disease and who underwent echocardiographic measurements of aortic valve sclerosis (AVS), mitral annular calcification (MAC), and aortic annular calcification (AAC). We used logistic regression models to estimate associations of mineral metabolism markers with AVS, MAC, and AAC after adjustment for relevant confounding variables, including kidney function. RESULTS: The respective prevalences of AVS, MAC, and AAC were 54%, 39%, and 44%. Each 0.5 mg/dl higher serum phosphate concentration was associated with greater adjusted odds of AVS (odds ratio [OR]: 1.17, 95% confidence interval [CI]: 1.04 to 1.31, p = 0.01), MAC (OR: 1.12, 95% CI: 1.00 to 1.26, p = 0.05), and AAC (OR: 1.12, 95% CI: 0.99 to 1.25, p = 0.05). In contrast, serum calcium, parathyroid hormone, and 25-hydroxyvitamin D concentrations were not associated with aortic or mitral calcification. CONCLUSIONS: Higher serum phosphate levels within the normal range were associated with valvular and annular calcification in a community-based cohort of older adults. Phosphate may be a novel risk factor for calcific aortic valve disease and warrants further study.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: Kemal Akat; Jens Johannes Kaden; Fabian Schmitz; Silke Ewering; Anja Anton; Sebastian Klomfass; Rainer Hoffmann; Jan Rudolf Ortlepp Journal: Am J Cardiol Date: 2010-03-15 Impact factor: 2.778
Authors: Y Agmon; B K Khandheria; I Meissner; J R Sicks; W M O'Fallon; D O Wiebers; J P Whisnant; J B Seward; A J Tajik Journal: J Am Coll Cardiol Date: 2001-09 Impact factor: 24.094
Authors: Nalini M Rajamannan; Malayannan Subramaniam; David Rickard; Stuart R Stock; Janis Donovan; Margaret Springett; Thomas Orszulak; David A Fullerton; A J Tajik; Robert O Bonow; Thomas Spelsberg Journal: Circulation Date: 2003-04-28 Impact factor: 29.690
Authors: J M Gardin; N D Wong; W Bommer; H S Klopfenstein; V E Smith; B Tabatznik; D Siscovick; S Lobodzinski; H Anton-Culver; T A Manolio Journal: J Am Soc Echocardiogr Date: 1992 Jan-Feb Impact factor: 5.251
Authors: Elaine E Wirrig; M Victoria Gomez; Robert B Hinton; Katherine E Yutzey Journal: Arterioscler Thromb Vasc Biol Date: 2015-02-26 Impact factor: 8.311
Authors: Rupal Mehta; Alexander Hodakowski; Xuan Cai; Kris E Lee; Bryan R Kestenbaum; Ian H de Boer; Amani Fawzi; Tien Yin Wong; Joachim Ix; Barbara Klein; Ronald Klein; Tamara Isakova Journal: Ophthalmic Epidemiol Date: 2017-04-12 Impact factor: 1.648
Authors: Aeron Small; Daniel Kiss; Jay Giri; Saif Anwaruddin; Hasan Siddiqi; Marie Guerraty; Julio A Chirinos; Giovanni Ferrari; Daniel J Rader Journal: Arterioscler Thromb Vasc Biol Date: 2017-02-02 Impact factor: 8.311
Authors: Cassianne Robinson-Cohen; Leila R Zelnick; Andrew N Hoofnagle; Pamela L Lutsey; Gregory Burke; Erin D Michos; Steven J C Shea; Russell Tracy; David S Siscovick; Bruce Psaty; Bryan Kestenbaum; Ian H de Boer Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Daniele Massera; Shuo Xu; Traci M Bartz; Anna E Bortnick; Joachim H Ix; Michel Chonchol; David S Owens; Eddy Barasch; Julius M Gardin; John S Gottdiener; John R Robbins; David S Siscovick; Jorge R Kizer Journal: Arch Osteoporos Date: 2017-05-30 Impact factor: 2.617
Authors: M Victoria Gomez-Stallons; Elaine E Wirrig-Schwendeman; Keira R Hassel; Simon J Conway; Katherine E Yutzey Journal: Arterioscler Thromb Vasc Biol Date: 2016-05-19 Impact factor: 8.311